Cardiac Valve Market Research Report Information By Types (Mechanical Valves, Tissue/Bioprosthetic Valves, Transcatheter Heart Valves/Percutaneous Heart Valves And Others), By Position (Mitral Valve, Aortic Valve And Other Position), By Treatment (Cardiac Valve Replacement, Cardiac Valve Repair And Other), By End User (Cardiac Research Institute, Hospital & Clinics, Specialty Centers And Others), and By Region (North America, Europe, Asia-Pacific, and Rest Of The World) – Market Forecast Till 2032

Global Cardiac Valve Market Overview

Cardiac Valve Market Size was valued at USD 7.2 Billion in 2022. The Cardiac Valve market industry is projected to grow from USD 7.7 Billion in 2023 to USD 12.7 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.50% during the forecast period (2023 - 2032). The burden of valvular heart disease is increasing, and individuals are living more sedentary lifestyles, are the key market drivers enhancing the market growth.

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Cardiac Valve Market Trends

• Rise in burden exerted by valvular heart diseases is driving the market growth

Increased geriatric population, shift in people's lifestyles from active to sedentary, novel developments in heart valves, increased awareness of surgical treatment options, and rising demand for minimally invasive surgeries are all factors driving the market's expansion. For instance, the American College of Cardiology estimates that every year, heart valve disease affects about 5 million Americans. However, some of the key constraints inhibiting the market's growth include the high cost of cardiac valves and the availability of other solutions for treating heart valve illness. Another significant factor influencing the heart valve repair and replacement market is the ability of computational tools to mimic additional fluid mechanics properties like pressure decreases, regurgitation volumes, or turbulence. Additionally, the availability of computational techniques enables precise diagnosis of valvar illness, which results in effective therapy and expands the market for cardiac valve repair and replacement.

The market for Cardiac Valve devices and equipment has been driven by the growing demand for transcatheter aortic valve replacement (TAVR) procedures as the prevalence of valvular heart disease has increased. The aortic valve of the heart is impacted by the valvular heart ailment known as aortic stenosis. A minimally invasive surgical procedure used to treat it is called TAVR. The aortic valve stiffens as a result of aortic stenosis, obstructing normal blood flow. The damaged aortic valve is replaced using a transcatheter valve. The Society of Thoracic Surgeons (STS)/American College of Cardiology (ACC) TVT Registry study found that volumes had risen annually. 2019 marked the first year that TAVR overcame all variations of surgical aortic valve replacement (SAVR). The number of TAVR performed each year is rising in accordance with the FDA's clearance of the procedure for low-risk patients, and in 2019 the overall volume of TAVR (72,991) surpassed all other types of SAVR (57,626). The frequency of TAVR surgeries will probably increase along with the prevalence of valvular heart disease, which will lead to a rise in the demand for transcatheter valves and, in turn, a rise in the market for cardiac valves.

The rising incidence of heart valve illness and the rising number of novel and improved cardiac valves receiving regulatory approvals are the key drivers driving the market's expansion. The market is expanding as a result of the rising incidence of heart valve disease, which is a significant component. For instance, rheumatic heart disease affects 39 million people worldwide, according to the World Heart Federation 2022. It is a condition when rheumatic fever has permanently affected the heart valves. Thus, driving the Cardiac Valve market revenue.

Cardiac Valve Market Segment Insights

Cardiac Valve Treatment Insights

The  Cardiac Valve market segmentation, based on Treatment, includes cardiac wall repair, cardiac wall replacement and others. Cardiac wall repair segment dominated the  market in 2022. The increasing prevalence of cardiovascular diseases can be blamed for this.

Cardiac Valve Type Insights

The  Cardiac Valve market segmentation, based on Type, includes mechanical valves, tissue/bioprosthetic valves, transcatheter heart valves/percutaneous heart valves, and others. The tissue/bioprosthetic valves segment dominated the  market in 2022. The market share of the mechanical valve segment is being constrained by the dominance of the tissue valve market due to the advent of bioprosthetic valves and their advantages, which include strength, flexibility, and a reduced need for anticoagulants. Other valves will also have steady growth over the forecasted time.

Cardiac Valve Position Insights

The  Cardiac Valve market segmentation, based on Position, includes mitral valve, aortic valve, and other position. Mitral valve segment dominated the  cardiac valve market in 2022. This is because cardiovascular disease is becoming more common as a result of factors including smoking, obesity, inactivity, and other stressors on the cardiovascular system.

Cardiac Valve End User Insights

The  Cardiac Valve market segmentation, based on End User, includes hospital & clinics, specialty centers, cardiac research institute, and others. The hospital & clinics segment dominated the  Cardiac Valve market in 2022. This is because of better government spending, an increase in hospital procedures, and better vulvar disease management. Cardiac Valve Market Value is developing as a result of specialty clinics, as well as other market sectors.

Figure 1  Cardiac Valve Market, by End User, 2022 & 2032 (USD Billion)

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Cardiac Valve Regional Insights

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North America Cardiac Valve Market dominated this market in 2022 (45.80%). This is due to an increase in medical knowledge, new product introductions, and regulatory rules that make it simple to produce and maintain heart valve devices. In addition, the rising frequency of lifestyle diseases like diabetes and obesity is a significant component in the region's domination. Further, the U.S. Cardiac Valve market held the largest market share, and the Canada Cardiac Valve market was the fastest growing market in the North America region.

Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2  CARDIAC VALVE MARKET SHARE BY REGION 2022 (USD Billion)

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe Cardiac Valve market accounted for the healthy market share in 2022. The high frequency of heart valve problems, product improvements, the volume of heart valve replacement surgeries, and the well-established healthcare infrastructure are the main drivers of the market's growth. Further, the German Cardiac Valve market held the largest market share, and the U.K Cardiac Valve market was the fastest growing market in the European region

The Asia Pacific Cardiac Valve market is expected to register significant growth from 2023 to 2032. This is because aortic stenosis and other cardiac illnesses are becoming more common, healthcare infrastructure is increasing in places like China and India, and industry participants are constantly looking for opportunities to invest in new markets. For instance, aortic stenosis is thought to affect 1 in 8 geriatric Australians, according to information provided by Hope for Hearts. Additionally, it was calculated that at least 97,000 Australians over the age of 55 suffer from severe aortic stenosis (AS). Moreover, China’s Cardiac Valve market held the largest market share, and the Indian Cardiac Valve market was the fastest growing market in the Asia-Pacific region.

Cardiac Valve Key Market Players & Competitive Insights

Leading market players are investing heavily in research and development in order to expand their product lines, which will help the Cardiac Valve market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their  footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, Cardiac Valve industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the  Cardiac Valve industry to benefit clients and increase the market sector. In recent years, the Cardiac Valve industry has offered some of the most significant advantages to medicine. Major players in the Cardiac Valve market, including Medtronic, Edwards Lifesciences Corporation, Boston Scientific Corporation, LivaNova PLC, Abbott, CryoLife, Inc, On-X Life Technologies, Inc., Colibri Heart Valve, JenaValve Technology, Inc., and TTK HealthCare, are attempting to increase market demand by investing in research and development Products.

An organisation that develops, produces, and markets devices for structural heart disease, critical care, and surgical monitoring is called Edwards Lifesciences Corp (Edwards Lifesciences). The company sells transcatheter heart valves, pressure monitoring equipment, hemodynamic monitoring equipment, surgical valve replacement and repair devices, as well as other tools and accessories. The management of clotting, hypotension, and sepsis, as well as transcatheter aortic valve replacement (TAVR), blood conservation, infection control, and improved surgical recovery are just a few therapies that its products are used in. The business sells its goods directly to consumers as well as through a network of independent distributors in regions like North America, Europe, and Asia-Pacific. The American city of Irvine serves as the headquarters of Edwards Lifesciences. The MITRIS RESILIA valve was approved by the US Food and Drug Administration (FDA) in March 2022 for Edwards Lifesciences. It is a tissue valve replacement made especially for the mitral location of the heart.

The mission of JenaValve Technology, Inc., a developer and producer of transcatheter aortic valve replacement (TAVR) systems, is to enhance the quality of life for people with structural heart diseases. Because of an anatomically based locator fixation and dual sealing valve design, the company's technology uses porcine pericardial tissue and a self-expanding nitinol frame with a transfemoral delivery system that does not require rapid pacing. This enables patients with ease of use, decreased risks of paravalvular regurgitation, and durability of hemodynamic results. With the Chinese company Peijia Medical Limited, JenaValve Technology, Inc. engaged into a strategic investment and exclusive technology licencing deal in January 2022.

Key Companies in the Cardiac Valve market include

• Medtronic


• Edwards Lifesciences Corporation


• Boston Scientific Corporation


• LivaNova PLC


• Abbott


• CryoLife, Inc


• On-X Life Technologies, Inc.


• Colibri Heart Valve


• JenaValve Technology, Inc.


• TTK HealthCare

Cardiac Valve Industry Developments

September 2019 Transcatheter aortic valve replacement (TAVR) system Evolut PRO+ has been made available in the United States, according to Medtronic.

September 2019 TriClip, a transcatheter tricuspid valve repair for the treatment of tricuspid regurgitation, was the subject of the TRILUMINATE pivotal trial that was started by Abbott.

Cardiac Valve Market Segmentation

Cardiac Valve Treatment Outlook

• Cardiac Wall Repair


• Cardiac Wall Replacement


• Others

Cardiac Valve Type Outlook

• Mechanical Valves


• Tissue/Bioprosthetic Valves


• Transcatheter Heart Valves/Percutaneous Heart Valves


• Others

Cardiac Valve Position Outlook

• Mitral Valve


• Aortic Valve


• Other Position

Cardiac Valve End User Outlook

• Hospital & Clinics


• Specialty Centers


• Cardiac Research Institute


• Others

Cardiac Valve Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America